Castle Biosciences (CSTL) EBIT Margin (2018 - 2026)

Castle Biosciences has disclosed EBIT Margin across 9 years of filings, most recently posting 22.0% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 22.0%, up 974.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 9.79% (down 582.0% YoY), and the FY2025 annual result was 12.44%, down 1505.0% from the prior year.
• EBIT Margin came in at 22.0% for Q1 2026 at Castle Biosciences, down from 4.4% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 5.92% in Q3 2024 to a low of 91.3% in Q1 2022.
• The 5-year median for EBIT Margin is 11.4% (2022), against an average of 24.96%.
• Across the five-year window, EBIT Margin slumped 7252 bps in 2022 and surged 6749 bps in 2024, its largest moves.
• Castle Biosciences' EBIT Margin stood at 59.55% in 2022, then surged by 86 bps to 8.56% in 2023, then soared by 155 bps to 4.69% in 2024, then sank by 194 bps to 4.4% in 2025, then sank by 400 bps to 22.0% in 2026.
• The last three EBIT Margin figures came in at 22.0% (Q1 2026), 4.4% (Q4 2025), and 8.19% (Q3 2025), per Business Quant data.